^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PV-001-DC

    i
    Other names: PV-001-DC, autologous monocyte-derived lysate pulsed dendritic cells
    Associations

    News

    Trials
    Company:
    PrimeVax
    Drug class:
    Immunostimulant, Cytotoxic T lymphocyte stimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    BRAF mutation
    |
    PV-001-DC • PV-001-DV
    10ms
    Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PV-001-DC • PV-001-DV
    10ms
    Arm 1: Lysate Pulsed Dendritic Cells (PV-001-DC) in Patients With Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PV-001-DC • PV-001-DV
    almost2years
    Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    BRAF mutation
    |
    PV-001-DC • PV-001-DV
    almost2years
    Intratumoral Injection of PV-001-DV Plus DC in Patients With Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Sep 2022 --> Sep 2023
    Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PV-001-DC • PV-001-DV
    over2years
    Arm 3: Intratumoral Injection of PV-001-DV in Combination With Infusion of PV-001-DC in Patients With Advanced Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Sep 2023 --> Dec 2022 | Trial primary completion date: Jan 2023 --> Sep 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    PV-001-DC • PV-001-DV
    over2years
    Arm 2: Intratumoral Injection of Dengue Virus-1 #45AZ5 (PV-001-DV) in Patients With Advanced Melanoma (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, PrimeVax Immuno-Oncology Inc. | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Jan 2022 --> Sep 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    BRAF mutation
    |
    PV-001-DC • PV-001-DV